Study Announcements

NN107 Fragile X Grant Release

Rush University Medical Center Awarded $11.5 Million for Fragile X Research
Promising New Drug Therapy for Language Learning

NN103 BeatMG trial achieves enrollment goal

The NN103 BeatMG Study Team is pleased to announce that the study has reached its goal of 50 randomized participants as of April 19th, 2016!  Please click here for official

NN102 SPRINT MS Patient Webinar

Please find the NN102 SPRINT MS Patient webinar posted below. For more information about this study, or if you have any questions, please contact Michelle McGovern (MMCCOURT1@mgh.harvard.edu) or Akshata Ashokkummar (AASHOKKUMAR@PARTNERS.ORG).

Patient Webinar

NN101 SMA Biomarker Principal Investigator speaks at Cure SMA 2015 Researcher meeting

Please see this article describing a talk at the Cure SMA 2015 Researcher meeting related to the NN101 SMA Biomarker study.  Speaking on initial results was Stephen Kolb, MD, from The Ohio State University.  He is the principal investigator for the study.

NeuroNEXT’s Multicenter Trial of Rituximab in Myasthenia Gravis Announces Addition of Clinical Study Sites

 

Tuesday, March 3, 2015

The NN103 Study Team is pleased to announce the addition of 11 NeuroNEXT Clinical Study Sites (CSS) across the US. One CSS has already been activated for enrollment, and 10 more are in the process of being activated. This will bring the total number of enrolling clinical study sites to 26.

Study Description:

A Phase 2 Trial of Rituximab in Myasthenia Gravis (NN103)

Pages